Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review

Abstract

Background

Deep vein thrombosis (DVT) and pulmonary embolism (PE) together are called venous thromboembolism (VTE) and impose a high economic burden on healthcare systems. Thousands of people are hospitalized annually due to benign and treatable diseases but die due to PE; with the adoption of appropriate prevention, these deaths can be prevented.

Objective

To investigate the cost-effectiveness of using rivaroxaban versus enoxaparin in published economic analyses for prevention of VTE after total knee (TKR) or hip replacement (THR).

Method

In a systematic review electronic searches were performed on various online databases, including PubMed, Web of science, Embase, Scopus, Health Economic Evaluations Database (HEED), and ProQuest. The inclusion criteria were: studies that were conducted on the cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of VTE after TKR and THR; cost-effectiveness studies conducted using decision analysis models based on the economic evaluation approach; studies with available full-text papers; and studies written in English and published between 2007 and 2019. The exclusion criteria were: studies with partial cost effectiveness (such as effectiveness assessment, cost assessment, quality-of-life assessment); studies written in languages other than English; and all protocols, conference abstracts, and letters to the editor. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to qualitatively evaluate the studies.

Results

Of a total of 537 initial studies, nine papers met the inclusion criteria. The time scope of studies ranged from 3 months to 5 years. Among the selected studies, some studies had included discount rates (n = 4) and the other studies did not utilize discount rates and were set to zero percent by default (n = 5). In all studies, direct medical costs, including costs related to the prevention, diagnosis, and treatment of VTE and PE, and management and monitoring of treatment costs were reviewed.

Conclusion

The results of this systematic review showed that using rivaroxaban in patients undergoing total knee or hip replacement reduced costs and increased quality of life. However, since most of the studies had been conducted in developed countries, it is not possible to generalize the results to developing countries. Nonetheless, given that rivaroxaban is administered orally and does not require continuous monitoring, it will be less costly for patients and health systems and is more appropriate to administer it as a thromboprophylactic drug following total knee or hip replacement surgery.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Aslan A, Khorami R, Rezaii J, Godarzi M, Abbasi DZ. Drug updates for prevention and treatment of venous thromboembolism in orthopedic surgeries. Iranian J Cardiovasc Nurs. 2017;6(2):66–73.

    Google Scholar 

  2. 2.

    Beckman MG, Abe K, Barnes K, Bartman B, Brady PJ, Hooper WC. Strategies and partnerships toward prevention of healthcare-associated venous thromboembolism. J Hosp Med. 2016;11(Suppl 2):S5.

    Article  Google Scholar 

  3. 3.

    Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf. 2013;22(10):809–15.

    Article  Google Scholar 

  4. 4.

    Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J Cardiovasc Pharmacother. 2014;35(43):3033–73.

    CAS  Google Scholar 

  5. 5.

    Heisen M, Treur MJ, Heemstra HE, Giesen EB, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. J Med Econ. 2017;20(8):813–24.

    Article  Google Scholar 

  6. 6.

    Health Select Committee. The prevention of venous thromboembolism in hospitalised patients. London: The Stationery Office Limited; 2005.

    Google Scholar 

  7. 7.

    Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations-United States, 2007–2009.

  8. 8.

    Rathbun S. The surgeon general’s call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation. 2009;119(15):e480–2.

    Article  Google Scholar 

  9. 9.

    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):338–400.

    Article  Google Scholar 

  10. 10.

    Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism. Curr Med Res Opin. 2010;26(10):2465–73.

    Article  Google Scholar 

  11. 11.

    Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98(10):756–64.

    CAS  Article  Google Scholar 

  12. 12.

    Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4):S495–501.

    Article  Google Scholar 

  13. 13.

    Habibzadeh H, Mohammadi A, Safari MB, Khalkhali HR, Rezaeipour N. The effect of care plan based on nutrition and exercise on deep vein thrombosis in patients undergoing lower limb orthopedic surgery in Urmia Imam Khomeini Hospital in 1391. J Urmia Nurs Midwifery Fac. 2013;11(9):680–7.

    Google Scholar 

  14. 14.

    Derman PB, Fabricant PD, David G. The role of overweight and obesity in relation to the more rapid growth of total knee arthroplasty volume compared with total hip arthroplasty. J Bone Jt Surg. 2014;96(11):922–8.

    Article  Google Scholar 

  15. 15.

    Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017;35(5):517–35.

    Article  Google Scholar 

  16. 16.

    Moghtadaee M, Shahhoseini GH, Farahini H, Yegane A, Rajabpour S. Dabigatran etexilate, a novel oral direct thrombin inhibitor, for preventing thromboembolic events after knee replacement arthroplasty. Tehran Univ Med J. 2012;69(11):725–9.

    Google Scholar 

  17. 17.

    Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thromb Haemost. 2013;110(11):987–94.

    CAS  Article  Google Scholar 

  18. 18.

    Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. J Thromb Haemost. 2010;104(10):760–70.

    CAS  Article  Google Scholar 

  19. 19.

    National Center for Biotechnology Information. PubChem Database. Rivaroxaban, CID = 9875401, https://pubchem.ncbi.nlm.nih.gov/compound/Rivaroxaban. Accessed 15 May 2020.

  20. 20.

    Schellack G, Modau T, Schellack N. Clinical overview of venous thromboembolism. S Afr Fam Pract. 2016;58(1):39–45.

    Google Scholar 

  21. 21.

    Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29(2):117–22.

    Article  Google Scholar 

  22. 22.

    McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics. 2009;27(10):829–46.

    Article  Google Scholar 

  23. 23.

    Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):601–15.

    Article  Google Scholar 

  24. 24.

    Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US Payer’s perspective. Pharmacoecon Open. 2012;30(2):87–101.

    Article  Google Scholar 

  25. 25.

    Zindel S, Stock S, Müller D, Stollenwerk B. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German Healthcare Setting. BMC Health Serv Res. 2012;12(1):192.

    Article  Google Scholar 

  26. 26.

    McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, et al. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian analysis using the Ontario Ministry of Health perspective. J Med Econ. 2012;15(5):817–28.

    Article  Google Scholar 

  27. 27.

    Neves JR, Folkerts K, Umbelino S, Santos IF. Cost-effectiveness of rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery in Portugal. Rev Port Farmacoter. 2014;6:16–23.

    Google Scholar 

  28. 28.

    Yan X, Gu X, Xu Z, Lin H, Wu B. Cost-effectiveness of different strategies for the prevention of venous thromboembolism after total hip replacement in China. Adv Ther. 2017;34(2):466–80.

    Article  Google Scholar 

  29. 29.

    Fantom JN, Umar S. The World Bank’s classification of countries by income (English). Policy Research working paper; no. WPS 7528. Washington, D.C; 2016: World Bank Group

  30. 30.

    Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107–14.

    PubMed  Google Scholar 

  31. 31.

    van Korlaar IM, Vossen CY, Rosendaal FR, Bovill EG, Cushman M, Naud S, Kaptein AA. The impact of venous thrombosis on quality of life. Thromb Res. 2004;114(1):11–8.

    Article  Google Scholar 

  32. 32.

    Griffin XL, McBride D, Nnadi C, Reed MR, Rossiter ND. “Don’t shoot the messengers…..”: the new NICE guidance for the prevention of venous thromboembolism in adults–fake news or a real opportunity? Bone Jt J. 2018;1136–1137.‏

  33. 33.

    Rodarte RR, Guimarães JA, Franco JS, Fonseca L, Nascimento V, Aramburu JP, et al. Systematic review of prophylaxis for venous thromboembolism after knee arthroplasty: enoxaparin versus rivaroxaban. Rev Col Bras Cir. 2019;46(2):e2075.

    Article  Google Scholar 

  34. 34.

    Huang HF, Li SS, Yang XT, Xie Q, Tian XB. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: a meta-analysis. Medicine. 2018; 97(48).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ali Abutorabi.

Ethics declarations

This article does not contain clinical studies or patient data.

Conflict of interest

The authors declare that they have no conflicts of interest.

Funding

This study was part of a PhD thesis supported by the Iran University of Medical Sciences (IUMS/SHMIS with Grant no: 98-2-37-15593 and with ethical code IR.IUMS.REC.1398.534).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rashki Kemmak, A., Abutorabi, A. & Alipour, V. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review. Clin Drug Investig (2020). https://doi.org/10.1007/s40261-020-00940-4

Download citation